SREBP1 Antibody - #AF4728

(8)   (18)  
Product: SREBP1 Antibody
Catalog: AF4728
Description: Rabbit polyclonal antibody to SREBP1
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Horse, Sheep, Dog, Chicken
Mol.Wt.: 122kDa; 122kD(Calculated).
Uniprot: P36956
RRID: AB_2811173

View similar products>>

   Size Price Inventory
 50ul $250 In stock
 100ul $350 In stock
 200ul $450 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Horse(82%), Sheep(100%), Dog(100%), Chicken(83%)
Clonality:
Polyclonal
Specificity:
SREBP1 Antibody detects endogenous levels of total SREBP1.
RRID:
AB_2811173
Cite Format: Affinity Biosciences Cat# AF4728, RRID:AB_2811173.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ADD 1; bHLHd1; Class D basic helix-loop-helix protein 1; D630008H06; Processed sterol regulatory element-binding protein 1; SRBP1_HUMAN; SREBF 1; SREBF1; SREBP 1; SREBP 1c; SREBP-1; SREBP1; Sterol regulatory element binding protein 1; Sterol Regulatory Element Binding Transcription Factor 1 / Protein 1; Sterol regulatory element binding transcription factor 1; Sterol regulatory element-binding transcription factor 1;

Immunogens

Immunogen:
Uniprot:

P36956(SRBP1_HUMAN) >>Visit HPA database.

Gene(ID):
SREBF1(6720)
Expression:
P36956 SRBP1_HUMAN:

Expressed in a wide variety of tissues, most abundant in liver and adrenal gland. In fetal tissues lung and liver shows highest expression. Isoform SREBP-1C predominates in liver, adrenal gland and ovary, whereas isoform SREBP-1A predominates in hepatoma cell lines. Isoform SREBP-1A and isoform SREBP-1C are found in kidney, brain, white fat, and muscle.

Sequence:
MDEPPFSEAALEQALGEPCDLDAALLTDIEDMLQLINNQDSDFPGLFDPPYAGSGAGGTDPASPDTSSPGSLSPPPATLSSSLEAFLSGPQAAPSPLSPPQPAPTPLKMYPSMPAFSPGPGIKEESVPLSILQTPTPQPLPGALLPQSFPAPAPPQFSSTPVLGYPSPPGGFSTGSPPGNTQQPLPGLPLASPPGVPPVSLHTQVQSVVPQQLLTVTAAPTAAPVTTTVTSQIQQVPVLLQPHFIKADSLLLTAMKTDGATVKAAGLSPLVSGTTVQTGPLPTLVSGGTILATVPLVVDAEKLPINRLAAGSKAPASAQSRGEKRTAHNAIEKRYRSSINDKIIELKDLVVGTEAKLNKSAVLRKAIDYIRFLQHSNQKLKQENLSLRTAVHKSKSLKDLVSACGSGGNTDVLMEGVKTEVEDTLTPPPSDAGSPFQSSPLSLGSRGSGSGGSGSDSEPDSPVFEDSKAKPEQRPSLHSRGMLDRSRLALCTLVFLCLSCNPLASLLGARGLPSPSDTTSVYHSPGRNVLGTESRDGPGWAQWLLPPVVWLLNGLLVLVSLVLLFVYGEPVTRPHSGPAVYFWRHRKQADLDLARGDFAQAAQQLWLALRALGRPLPTSHLDLACSLLWNLIRHLLQRLWVGRWLAGRAGGLQQDCALRVDASASARDAALVYHKLHQLHTMGKHTGGHLTATNLALSALNLAECAGDAVSVATLAEIYVAAALRVKTSLPRALHFLTRFFLSSARQACLAQSGSVPPAMQWLCHPVGHRFFVDGDWSVLSTPWESLYSLAGNPVDPLAQVTQLFREHLLERALNCVTQPNPSPGSADGDKEFSDALGYLQLLNSCSDAAGAPAYSFSISSSMATTTGVDPVAKWWASLTAVVIHWLRRDEEAAERLCPLVEHLPRVLQESERPLPRAALHSFKAARALLGCAKAESGPASLTICEKASGYLQDSLATTPASSSIDKAVQLFLCDLLLVVRTSLWRQQQPPAPAPAAQGTSSRPQASALELRGFQRDLSSLRRLAQSFRPAMRRVFLHEATARLMAGASPTRTHQLLDRSLRRRAGPGGKGGAVAELEPRPTRREHAEALLLASCYLPPGFLSAPGQRVGMLAEAARTLEKLGDRRLLHDCQQMLMRLGGGTTVTSS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Sheep
100
Dog
100
Chicken
83
Horse
82
Bovine
0
Xenopus
0
Zebrafish
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P36956 As Substrate

Site PTM Type Enzyme
T59 Phosphorylation
S63 Phosphorylation Q16539 (MAPK14)
S117 Phosphorylation P27361 (MAPK3) , P28482 (MAPK1) , P45983 (MAPK8)
K123 Sumoylation
K256 Ubiquitination
T275 Phosphorylation
S312 Phosphorylation
K313 Ubiquitination
R321 Methylation
K324 Acetylation
K324 Ubiquitination
K333 Acetylation
S337 Phosphorylation P57059 (SIK1)
S338 Phosphorylation P57059 (SIK1) , P17612 (PRKACA)
K342 Ubiquitination
K347 Ubiquitination
K356 Ubiquitination
K359 Ubiquitination
S360 Phosphorylation
K365 Ubiquitination
K379 Ubiquitination
K381 Ubiquitination
S396 Phosphorylation P54646 (PRKAA2)
K398 Ubiquitination
S402 Phosphorylation P57059 (SIK1)
K418 Sumoylation
T424 Phosphorylation
T426 Phosphorylation P49841 (GSK3B) , Q16539 (MAPK14)
S430 Phosphorylation P49841 (GSK3B)
S434 Phosphorylation P49841 (GSK3B)
S439 Phosphorylation P06493 (CDK1)
S448 Phosphorylation
S450 Phosphorylation
S455 Phosphorylation
S457 Phosphorylation
S467 Phosphorylation P53350 (PLK1)
K470 Ubiquitination
S486 Phosphorylation
Y567 Phosphorylation
K587 Ubiquitination
K675 Ubiquitination
K727 Ubiquitination
K924 Methylation
K924 Ubiquitination
K934 Ubiquitination
K947 Ubiquitination
S1020 Phosphorylation
S1027 Phosphorylation
S1049 Phosphorylation
S1060 Phosphorylation
K1070 Ubiquitination
K1121 Ubiquitination

Research Backgrounds

Function:

Transcriptional activator required for lipid homeostasis. Regulates transcription of the LDL receptor gene as well as the fatty acid and to a lesser degree the cholesterol synthesis pathway (By similarity). Binds to the sterol regulatory element 1 (SRE-1) (5'-ATCACCCCAC-3'). Has dual sequence specificity binding to both an E-box motif (5'-ATCACGTGA-3') and to SRE-1 (5'-ATCACCCCAC-3').

PTMs:

At low cholesterol the SCAP/SREBP complex is recruited into COPII vesicles for export from the ER. In the Golgi complex SREBPs are cleaved sequentially by site-1 and site-2 protease. The first cleavage by site-1 protease occurs within the luminal loop, the second cleavage by site-2 protease occurs within the first transmembrane domain and releases the transcription factor from the Golgi membrane. Apoptosis triggers cleavage by the cysteine proteases caspase-3 and caspase-7.

Phosphorylated by AMPK, leading to suppress protein processing and nuclear translocation, and repress target gene expression. Phosphorylation at Ser-402 by SIK1 represses activity possibly by inhibiting DNA-binding (By similarity).

Subcellular Location:

Endoplasmic reticulum membrane>Multi-pass membrane protein. Golgi apparatus membrane>Multi-pass membrane protein. Cytoplasmic vesicle>COPII-coated vesicle membrane>Multi-pass membrane protein.
Note: Moves from the endoplasmic reticulum to the Golgi in the absence of sterols.

Nucleus.

Nucleus.

Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in a wide variety of tissues, most abundant in liver and adrenal gland. In fetal tissues lung and liver shows highest expression. Isoform SREBP-1C predominates in liver, adrenal gland and ovary, whereas isoform SREBP-1A predominates in hepatoma cell lines. Isoform SREBP-1A and isoform SREBP-1C are found in kidney, brain, white fat, and muscle.

Subunit Structure:

Forms a tight complex with SCAP in the ER membrane. Efficient DNA binding of the soluble transcription factor fragment requires dimerization with another bHLH protein. Interacts with LMNA. Interacts with CEBPA, the interaction produces a transcriptional synergy (By similarity).

Family&Domains:

The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.

Belongs to the SREBP family.

Research Fields

· Environmental Information Processing > Signal transduction > AMPK signaling pathway.   (View pathway)

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

References

1). Sirtuin 3‐mediated deacetylation of acyl‐CoA synthetase family member 3 by protocatechuic acid attenuates nonalcoholic fatty liver disease. British Journal of Pharmacology, 2020 (PubMed: 32520409) [IF=7.3]

Application: WB    Species: Mouse    Sample: livers

Figure 3. PCA promotes fatty acid metabolism through SIRT3 activation. (A-E) Western blotting and real-time PCR analysis of hepatic FASN, SREBP-1c, CPT1, Acox1 and PPARα protein (n=5) and mRNA (n=6) levels in mouse livers. *P< 0.05 vs. the WT ND group, #P< 0.05 vs. the WT HFD group, &P< 0.05 vs. the SIRT3−/− ND group. (F-I) The protein expression of FASN, SREBP-1c, CPT1, Acox1, PPARα and SIRT3 was measured by Western blotting (n=5). The mRNA levels of (J) FASN, SREBP-1c (K) CPT1, Acox1 and PPARα were measured with real-time PCR (n=6). *P< 0.05 vs. the si-Control group, #P< 0.05 vs. the si-Control+PA group, &P< 0.05 vs. the si-Control+PA+PCA group.
2). Targeting at cancer energy metabolism and lipid droplet formation as new treatment strategies for epigallocatechin-3-gallate (EGCG) in colorectal cancer cells. Journal of Functional Foods, 2021 [IF=5.6]

Application: WB    Species: Human    Sample: HCT116 cells

Fig. 3. Effects of EGCG on the expressions of the key enzymes and transcription factor of fatty acid de novo synthesis in HCT116 cells. (A) The expressions of ACLY, FASN, ACC, SCD1, and SREBP1c at the mRNA level as determined using qRT-PCR. (B-C) Western blot and densitometry analysis. The relative intensities of proteins were calculated after normalization to β-Actin. (D-E) Immunofluorescence staining and quantification of FASN, scale bar: 20 μm. Data represent the means ± SE from three independent experiments (A and C) or from three independent experiments with 2 duplicates (E). Statistical analysis was performed using one-way ANOVA with post hoc Bonferroni’s correction test. Groups containing different lowercase letters (a-e) indicate statistical significance at the level of p < 0.05.
3). Patchouli alcohol alleviates metabolic dysfunction-associated steatohepatitis via inhibiting mitochondria-associated endoplasmic reticulum membrane disruption-induced hepatic steatosis and inflammation in rats. International immunopharmacology, 2024 (PubMed: 38971107) [IF=5.6]
4). Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway. Drug Design, Development and Therapy, 2023 (PubMed: 37808345) [IF=4.8]

Application: WB    Species: Rat    Sample: liver tissue

Figure 5 Effects of Si-Ni-San (SNS) on the protein expressions related to lipid metabolism. The protein expressions of FAS, CPT-1, nuclear and cytosolic SREBP-1c and PPARα were determined by Western blot. (A and B) Typical bands of Western blot, (C–F) gray value of Western blot bands. The data are stated as the means ± SD. n = 3 *vs CON group (P < 0.05), #vs MOD group (P < 0.05). Liver was obtained from control group (CON), model group (MOD), low-dose SNS group (SNS-L), high-dose SNS group (SNS-H), and metformin group (MET).
5). The Role of cAMP-PKA Pathway in Lactate-Induced Intramuscular Triglyceride Accumulation and Mitochondria Content Increase in Mice. Frontiers in Physiology, 2021 (PubMed: 34588991) [IF=4.0]

Application: WB    Species: Mice    Sample: gastrocnemius

Figure 7 The expression levels of lipid metabolism-related proteins after chronic lactate and forskolin injection. (A) Western blot analysis and relative fold protein expression of lipolysis-related proteins. (B) Western blot analysis and relative fold protein expression of lipogenesis-related proteins. CP, chronic PBS treated group; CL, chronic lactate treated group; CF, chronic forskolin treated group; CD, chronic DMSO treated group; and CLF, chronic lactate and forskolin treated group. Relative expression levels were normalized to GAPDH. Three bands are used for statistics. The data are presented as the mean±SD, and significant differences among the groups were analyzed with one-way ANOVA. * p<0.05.
6). Tilianin Protects against Nonalcoholic Fatty Liver Disease in Early Obesity Mice. Biological and Pharmaceutical Bulletin, 2023 (PubMed: 36858570) [IF=2.0]

Application: WB    Species: Mouse    Sample: Liver tissue

Fig. 3. Tilianin Attenuated Aberrant Lipid Metabolism and Oxidative Stress in HFHC-Fed Mice The levels of (A) LDL-C, (B) HDL-C, and (C) TC in the liver. (D) Representative liver sections stained with Oil Red O. (E–I) The protein expression levels of ACC1, FAS, SREBP-1c and LXRα in the liver were analyzed by Western blotting. (J) ROS concentration in mice detected using DHE probe. (K) 4-HNE expression was analyzed by IHC analysis.
7). Intramuscular Mitochondrial Adaptation and Lipid Metabolic Alteration in Rats after Chronic High-intensity Interval Training (HIIT) of Different Training Periods. Research Square, 2022

Application: WB    Species: Rat    Sample:

FIGURE 3 | The expression levels of lipogenesis-related proteins after HIIT. (A) Western blot analysis of lipogenesis-related proteins. (B) Fold protein expression of SREBP-1C, FAS, and the ratio of P-ACC/ACC. Three bands are used for statistics. The data are presented as the mean±SD, and significant differences between the two groups were analyzed with the independent-samples t-test. *P
8). Efficacy of Ganshuang granules (肝爽颗粒) on non-alcoholic fatty liver and underlying mechanism: a network pharmacology and experimental verification. Journal of Traditional Chinese Medicine, 2024 (PubMed: 38213247)

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.